It was a interesting week in the stem cell sector, with new releases about MSCs, exosomes, Sertoli cells, and more. Check out this coverage of the stem cell industry and let me know what you think?
According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. One small but powerful company working in this area is AltuCell, a company whose mission is to find a cure to diabetes. In a recent peer-review article published in the journal Xenotransplantation (September 2016), AltuCell’s medical lead Dr. Giovanni Luca reported a preclinical breakthrough utilizing microencapsulated Sertoli cells to establish reversal of diabetes in a mouse model. An important voice in support of the recent findings was Dr. David White of the Schulich School of Medicine who released an article about the breakthrough titled, “A Cure for Type 2 Diabetes?”
What are exosomes? This is an important question, because exosomes have recently exploded in popularity. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes. Today, there are more than 4,400 articles published about exosomes, of which 1,088 (~25%) were released in the 2016 calendar year. Clearly, there has been an explosion of interest in exosomes, making it important for the scientific community to understand the functionality and importance of these nano-sized vesicles.
BioInformant is honored to sponsor the World Stem Cell Summit 2016 in West Palm Beach, Florida, on December 6-9, 2016. The summit brings together more than 1,200 intelligent minds, putting brilliant speakers on stage and packing rooms with curious and eager listeners. In my opinion, it is the ultimate gathering for the stem cell community, because it attracts stakeholders from across the industry, including executives, investors, researchers, clinicians, advocates, and patients. Now celebrating its 12th year, the conference will feature 1,200+ attendees, 225+ speakers, 30,000 sq. feet of exhibit floor, and 90+ hours of programming. I also hooked you up with a $200 discount code, because I hope to see you there.
In this article, Dr. Daniel Kota, a mesenchymal stem cell (MSC) researcher, explores six questions that will direct the future of MSC research. According to Kota, one of the reasons that MSCs have not reached their full potential is that the authority of the cells does not come from their differentiation capacity, but from the ability to regulate the immune response and spark the body’s regenerative machinery. Therefore, he considers questions that include: Is MSC treatment better than using the whole mononuclear cell population (MNC)? What are the effects of scale up technologies on MSCs? To what degree does donor variability impact outcomes? His insights as a MSC researcher are priceless.
Pall Corporation, a global leader in bioprocess equipment and disposables, announced the signing of a commercial collaboration agreement with RoosterBio Inc, an innovative adult stem cell technology company. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). These systems will enable the BioPharmaceutical industry to accelerate product development, reduce clinical translation timelines and ultimately streamline the commercialization pathway for stem cell-based therapies.
This 175-page global strategic report reveals unexpected trends in stem cell publications, clinical trials, grants, patents, product launches, and partnerships. It identifies leading players within the stem cell marketplace, their little-known strategies for expansion, and the market share of each. Presenting thorough market size data, plus 5-year projections, the report also highlights findings from a survey of 289 stem cell scientists, giving you insider insights into the minds of your clients. Revealing both traditional metrics and social analytics from Google Trends and Google Search (this info used to be classified), this global report is your ultimate competitive edge. The market for stem cell products is expanding. Are you ready to compete?
President/CEO of BioInformant.com
“1st and Only Market Research Firm to Specialize in the Stem Cell Industry”